Skip to main content
Staff Login
Username
*
Enter your The Contraceptive Pipeline Database username.
Password
*
Enter the password that accompanies your username.
Log in
Forgot password
Toggle navigation
Norethindrone Acetate Patch
Product Overview
Development Status:
Active Development
Target:
Female
Mode:
Hormonal
Delivery Type:
Transdermal
Duration Type:
Short-acting
Description:
Norethindrone acetate transdermal delivery system (patch).
Updated date:
May 30, 2018
Vertical Tabs
Product Details
Active Pharmaceutical Ingredient (API):
norethindrone
Potential Multi-Purpose Technology (MPT):
No
Regimen:
weekly (3 weeks on, 1 week without patch)
Duration:
one week
Partner:
Actavis
Status
Project Phase:
Post-development
Project Stage:
Regulatory
Status Details:
Phase III completed in 2012. NDA filed with US FDA in 2013.
Programmatic Considerations
Additional Information
Footnotes:
Phase III study conducted by Watson Pharmaceuticals, which is now Actavis.
Download Product Report
